Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Multiple Attacks of Acute Migraine (0462-025)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient had at least a 6-month history of migraine, with or without aura~* Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions.~* Patient was judged to be in good health, apart from migraine~Exclusion Criteria:~* Patient was pregnant or a nursing mother.~* Patient had abused drugs or alcohol within 12 months prior to entering the study~* Patient had a history of cardiovascular disease~* Patient had clinically significant ECG abnormality~* Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening~* Patient received treatment with an investigational device or compound within 30 days of the study start~* Patient typically suffered from less then 1 or more than 8 attacks of migraine per month~* Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches~* Patient had prior exposure to rizatriptan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence 1 (Type: EXPERIMENTAL): Placebo-Rizatriptan-Rizatriptan-Rizatriptan
- Treatment Sequence 2 (Type: EXPERIMENTAL): Rizatriptan-Placebo-Rizatriptan-Rizatriptan
- Treatment Sequence 3 (Type: EXPERIMENTAL): Rizatriptan-Rizatriptan-Placebo-Rizatriptan
- Treatment Sequence 4 (Type: EXPERIMENTAL): Rizatriptan-Rizatriptan-Rizatriptan-Placebo
- Treatment Sequence 5 (Type: EXPERIMENTAL): Rizatriptan-Rizatriptan-Rizatriptan-Rizatriptan

Based on this trial design, predict the completion outcome and termination type (if applicable).